Hepatitis C treatment: where are we now?

File Description SizeFormat 
IJGM-127689-hepatitis-c-treatment--where-are-we-now-_021717.pdfPublished version2.04 MBAdobe PDFDownload
Title: Hepatitis C treatment: where are we now?
Author(s): Burstow, N
Mohamed, Z
Gomaa, AI
Sonderup, MW
Cook, NA
Waked, I
Spearman, CW
Taylor-Robinson, S
Item Type: Journal Article
Abstract: Chronic hepatitis C infection affects millions of people worldwide and confers significant morbidity and mortality. Effective treatment is needed to prevent disease progression and associated complications. Previous treatment options were limited to interferon and ribavirin regimens, which gave low cure rates and were associated with unpleasant side effects. The era of direct acting antiviral (DAA) therapies began with the development of the first-generation of NS3/4A protease inhibitors (PI) in 2011. They vastly improved outcomes for patients, particularly those with genotype 1 infection, the most prevalent genotype globally. Since then a multitude of DAAs have been licensed for use and outcomes for patients have improved further, with fewer side effects and cure rates approaching 100%. Recent regimens are interferon-free, and in many cases, ribavirin-free and involve a combination of DAA agents. This review summarises the treatment options currently available and discusses potential barriers that may delay the global eradication of hepatitis C.
Publication Date: 17-Feb-2017
Date of Acceptance: 19-Dec-2016
URI: http://hdl.handle.net/10044/1/43275
DOI: https://dx.doi.org/10.2147/IJGM.S127689
ISSN: 1178-7074
Publisher: Dove Medical Press
Start Page: 39
End Page: 52
Journal / Book Title: International Journal of General Medicine
Volume: 10
Copyright Statement: © 2017 Burstow et al. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License. The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Sponsor/Funder: Wellcome Trust
Wellcome Trust
Wellcome Trust
Wellcome Trust
Funder's Grant Number: 097816/Z/11/ZR
097816/Z/11/A
097816/Z/11/B
105603/Z/14/Z
Keywords: directly acting antivirals
hepatitis C
hepatitis C eradication
interferon-free regimens
protease inhibitors
ribavirin-free regimens
1103 Clinical Sciences
Publication Status: Published
Appears in Collections:Division of Surgery
Faculty of Medicine



Items in Spiral are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons